Circulating Tumor Cell Diagnostics Market

On 24 May 2022 the US Food and Drug Administration granted De Novo authorisation to ANGLE’s Parsortix PC1 system, the first device cleared to capture and harvest circulating tumor cells from the blood of patients with metastatic breast cancer for downstream analysis, and created a new device classification regulation, 21 CFR 866.6110, for the whole category. Douglas Insights values the circulating tumor cell diagnostics market at USD 1.02 billion in 2025 and forecasts USD 3.05 billion by 2035, a compound growth rate of 11.56%. The receipt is about 1.55 million blood samples processed for circulating tumor cells worldwide in 2025 at an average value of USD 660 per sample, across kits and reagents, instruments and systems, clinical testing services, single-cell analysis and software. Samples processed grow 11.0% a year as oncology drug developers and cancer centres use circulating tumor cells to follow metastatic disease, while value per sample rises 0.5% a year as single-cell characterisation adds to simple counting. The report sits within Douglas Insights coverage of in-vitro diagnostics and follows the published Douglas Insights methodology.

What are circulating tumor cell diagnostics, and what does the market include?

Circulating tumor cell diagnostics are tests and tools that find, count and analyse cancer cells shed from a tumour into the blood, and about 1.55 million samples were processed in 2025. Circulating tumor cells are extremely rare, often fewer than 10 in a 7.5 millilitre tube of blood that holds billions of blood cells, so every test starts by enriching them. Three technologies do that work: EpCAM-based immunomagnetic capture, which uses magnetic particles coated with antibodies against a protein on epithelial cancer cells; size-based microfluidic enrichment, which traps the larger and stiffer tumour cells in a cassette without labels; and negative depletion, which removes white blood cells and leaves the tumour cells behind. The cells are then counted, stained, or picked out one by one for genetic sequencing. The market counts kits and reagents, instruments and systems, clinical testing services and single-cell analysis and software, at manufacturer or laboratory realised price. Circulating tumour DNA tests, exosome tests, general cell-sorting instruments used outside cancer, and pathologist fees sit outside the boundary.

What did the FDA’s Parsortix decision change for circulating tumor cell diagnostics?

The FDA’s Parsortix decision gave circulating tumor cell diagnostics a second cleared route after 18 years in which one system defined the field. Menarini Silicon Biosystems’ CellSearch was cleared in 2004 for metastatic breast cancer and later for metastatic colorectal and prostate cancer, and it remains the only FDA-cleared system that counts circulating tumor cells to inform prognosis. CellSearch relies on EpCAM capture, which misses cells that lose the protein as they spread. Parsortix uses size-based microfluidic enrichment, harvests live cells for molecular testing and, under the new regulation, gives laboratories a cleared front end for their own assays. The decision does not allow Parsortix to make diagnostic claims on its own, so the value it creates sits in the laboratory tests built on top of it. Douglas Insights estimates size-based and microfluidic enrichment took about 30% of 2025 circulating tumor cell diagnostics value and grows to about 40% by 2035, while EpCAM-based capture falls from about 50% to about 42%.

How many cancer patients could use circulating tumor cell diagnostics?

About 20 million people were diagnosed with cancer in 2022, according to the International Agency for Research on Cancer, and 9.7 million died of it, so the pool for circulating tumor cell diagnostics is large. Circulating tumor cell testing is used mainly in metastatic disease, where cells are most common: in the study behind the CellSearch clearance, patients with metastatic breast cancer who had 5 or more circulating tumor cells per 7.5 millilitres had shorter survival than those with fewer. Douglas Insights estimates about 55% of 2025 clinical circulating tumor cell tests were for breast cancer, 20% for prostate cancer, 12% for lung cancer, 8% for colorectal cancer and 5% for other cancers. The International Agency for Research on Cancer expects new cases to reach about 35 million a year by 2050, which lifts the number of metastatic patients who could be monitored with a blood draw.

What drives circulating tumor cell diagnostics demand?

Drug development drives 62% of circulating tumor cell diagnostics value. Oncology drug makers use circulating tumor cells as exploratory endpoints, to select patients whose tumour cells carry a target and to track resistance without repeat tissue biopsies, and Douglas Insights estimates research and pharmaceutical laboratories took that 62% share of 2025 value. Trials in breast, prostate and lung cancer increasingly add a blood sample for circulating tumor cells at each visit, and Douglas Insights counts roughly 400 active interventional oncology trials that list circulating tumor cells as a measure. Research and pharmaceutical laboratories grow about 11% a year, keeping them the largest users through 2035.

Cleared enrichment systems are the second driver. The 24 May 2022 Parsortix decision and the classification regulation it created give hospital laboratories a cleared starting point, so a laboratory can validate a test for a gene or protein on the harvested cells rather than building the whole method itself. Douglas Insights estimates hospital laboratories and reference laboratories took about 38% of 2025 value, and clinical testing services grow 12.78% a year to USD 783 million by 2035 as more laboratories offer tests on harvested cells.

Single-cell analysis is the third driver. Picking out individual circulating tumor cells and sequencing them shows how a cancer is changing, including the resistance markers that ctDNA can miss when tumour cells release little DNA. Single-cell analysis and software hold 10% of 2025 value, USD 102 million, and are the fastest-growing segment at 15.27% a year, reaching USD 424 million by 2035, and value per sample rises 0.5% a year, from USD 660 to about USD 694, as more samples move from counting to characterisation.

The spread of cancer care in Asia is the fourth driver. China’s regulator has approved several domestic circulating tumor cell detection kits, Japanese and South Korean cancer centres run circulating tumor cell research programmes, and Douglas Insights estimates Asia Pacific samples grow about 14% a year to 2035, adding about 3 points to global circulating tumor cell diagnostics volume growth. China alone records about 4.8 million new cancer cases a year, the most of any country, and its large public cancer hospitals are adding liquid biopsy laboratories that can run both DNA and cell tests from the same blood draw.

What holds back the circulating tumor cell diagnostics market?

Three restraints cut the 2035 circulating tumor cell diagnostics figure to about USD 1.82 billion in the slower case. Competition from circulating tumour DNA comes first: the FDA approved the Guardant360 CDx and FoundationOne Liquid CDx blood tests in August 2020, and oncologists now choose DNA tests for most mutation testing because they are simpler, run on standard sequencers and are covered by many payers. Douglas Insights estimates circulating tumour DNA tests earn several times the value of circulating tumor cell diagnostics in breast and lung cancer.

Sensitivity comes second. Even in metastatic breast cancer, only about half of patients have 5 or more circulating tumor cells per 7.5 millilitres, and in early-stage disease the share with any detectable cells is far lower, which limits circulating tumor cell diagnostics to monitoring rather than screening. Reimbursement and laboratory economics come third: counting tests are paid a few hundred dollars in the United States and are rarely covered in Europe, and Biocept, a US liquid biopsy laboratory that offered circulating tumor cell testing, filed for liquidation in October 2023. Each 1-point change in sample growth moves the 2035 figure by about USD 287 million.

Which circulating tumor cell diagnostics segments carry the most value?

Kits and reagents lead with 46% of 2025 value. These circulating tumor cell diagnostics consumables earned USD 471 million, growing 11.28% a year to USD 1.37 billion, because every sample uses a collection tube, enrichment cassette or magnetic kit and staining reagents. Clinical testing services hold 23%, USD 235 million, growing 12.78% a year as laboratories build tests on cleared enrichment systems. Instruments and systems hold 21%, USD 215 million, and grow slowest at 8.29% a year, since each system processes thousands of samples over its life. Single-cell analysis and software hold 10%, USD 102 million, and are the fastest-growing segment at 15.27% a year as researchers sequence individual circulating tumor cells.

By technology, Douglas Insights estimates EpCAM-based immunomagnetic capture took about 50% of 2025 value, size-based microfluidic enrichment about 30% and negative depletion and other methods about 20%. By cancer type, breast cancer leads, followed by prostate cancer, lung cancer and colorectal cancer.

Which regions buy the most circulating tumor cell diagnostics, and which grows fastest?

North America buys the most, 46% of 2025 value, and Asia Pacific is the fastest-growing region at 14.43% a year. North American circulating tumor cell diagnostics sales reached USD 471 million in 2025, growing 10.73% a year to USD 1.30 billion, because most oncology trials that use circulating tumor cells run there and the only cleared systems launched there first. Europe holds 27%, USD 276 million, growing 10.43% a year, led by Germany, France, the UK, Italy and the Netherlands, where academic cancer centres run large circulating tumor cell research programmes. Asia Pacific holds 20%, USD 205 million, rising to USD 787 million by 2035 as China approves domestic kits and Japan and South Korea expand research. Latin America adds USD 40.9 million at 11.93% and the Middle East and Africa USD 30.7 million at 11.43%, both from small private-hospital and research bases.

Which companies supply circulating tumor cell diagnostics?

Circulating tumor cell diagnostics are fragmented: Douglas Insights estimates Menarini Silicon Biosystems holds about 14% of 2025 value and the five largest suppliers about 45%. Menarini Silicon Biosystems sells the CellSearch system and the DEPArray instrument, which sorts single cells for sequencing. Thermo Fisher Scientific, Miltenyi Biotec and STEMCELL Technologies supply the magnetic beads, depletion kits and reagents that research laboratories use to build their own circulating tumor cell methods, and QIAGEN sells the AdnaTest kits. ANGLE sells the Parsortix system cleared in May 2022, and Epic Sciences, RareCyte and Biolidics offer imaging platforms, testing services or label-free systems. Companies win on capture rate, cell viability, cleared claims and links to downstream sequencing. The wider blood-based breast cancer testing market is sized in our Breast Cancer Liquid Biopsy Market report.

How much do circulating tumor cell diagnostics cost?

Circulating tumor cell diagnostics cost an average USD 660 per sample in 2025, across a wide range. A research sample processed with a magnetic depletion kit and standard staining uses USD 100 to USD 300 of reagents, while a sample run on a cleared enrichment cassette with imaging costs USD 300 to USD 600 in consumables. Clinical counting tests in the United States are billed at several hundred dollars, and a single-cell sequencing workup on picked circulating tumor cells can cost USD 1,500 to USD 3,000 per sample. Enrichment and imaging instruments sell for about USD 100,000 to USD 350,000, and single-cell sorting systems at the top of that range. Douglas Insights expects the average value per sample to rise to about USD 663 in 2026 and USD 694 by 2035, as more samples move to characterisation, partly offset by cheaper kits from Chinese suppliers. Nucleic acid extraction behind downstream testing is sized in our Magnetic Bead-based Nucleic Acid Extraction Market report.

How could the circulating tumor cell diagnostics forecast change by 2035?

The circulating tumor cell diagnostics forecast ranges from USD 1.82 billion to USD 4.60 billion in 2035. The base case carries 11.0% growth in samples processed and 0.5% growth in value per sample, for an 11.56% revenue CAGR and USD 3.05 billion. The slower scenario, with circulating tumour DNA taking most monitoring, flat trial budgets and price pressure from low-cost kits, sets the legs at 7.0% and −1.0%, for 5.93% growth. The faster scenario, with a prognostic or treatment-selection claim cleared on the Parsortix route and payers covering tests in metastatic breast and prostate cancer, sets them at 14.5% and 1.5%, for 16.22% growth. Each 1-point change in sample growth moves the 2035 figure by about USD 287 million. Tissue sampling that circulating tumor cells partly replace is sized in our Biopsy Devices Market report.

Douglas Exclusive: the circulating tumor cell diagnostics assay clearance tracker

The Douglas Exclusive tracker lists every circulating tumor cell diagnostics system and assay with a regulatory clearance or CE mark in 12 countries, with its claim, cancer type, enrichment method and reimbursement status, and follows laboratory-developed tests built on the Parsortix and CellSearch platforms. Licence holders receive it as a maintained tab in the Excel model, updated as the FDA, China’s regulator and European notified bodies clear new claims.

Which regulations shape the circulating tumor cell diagnostics market?

Three layers of rules shape the circulating tumor cell diagnostics market, starting with the FDA classification regulation for cell enrichment devices created on 24 May 2022. Device clearance comes first: in the United States, 21 CFR 866.6110 sets special controls for devices that enrich circulating tumor cells, while CellSearch counting sits under earlier clearances; in Europe the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 requires notified-body review for most cancer tests, with transition periods extended in 2024. Laboratory rules come second: most clinical circulating tumor cell tests are laboratory-developed tests run under local accreditation. Reimbursement comes third: Medicare pays for circulating tumor cell counting under laboratory fee codes, and payers in Europe rarely fund the tests outside trials.

What methodology sits behind the circulating tumor cell diagnostics model?

The circulating tumor cell diagnostics model is built bottom-up from about 1.55 million samples processed in 2025 at an average USD 660 each. It covers 4 product segments, 3 enrichment technologies, 5 cancer types, 3 end users and 5 regions. Samples come from company disclosures on kit and cassette sales, instrument installed bases in 25 countries, trial registry counts and laboratory test volumes; prices come from list prices, laboratory fee schedules and company reports. Circulating tumour DNA tests, exosome tests and pathologist fees are excluded, and growth is decomposed as samples processed times value per sample. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.

Sources

1. US Food and Drug Administration De Novo DEN200062: Parsortix PC1 grant letter (2022)
2. eCFR 21 CFR 866.6110 (2022)
3. International Agency for Research on Cancer Global cancer burden growing, amidst mounting need for services (2024)
4. EUR-Lex Regulation (EU) 2017/746 on in vitro diagnostic medical devices (2017)